所有图片(1)

主要文件

COO原产地证书/COA分析证书

安全信息

安全和法规

Y0001416

Betamethasone dipropionate for peak identification

Name: Betamethasone dipropionate for peak identification
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

别名:

Betamethasone 17,21-dipropionate, 9α-Fluoro-16β-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17,21-dipropionate

登录查看公司和协议定价

所有图片(1)

About This Item

经验公式（希尔记法）:

C₂₈H₃₇FO₇

CAS号:

5593-20-4

分子量:

504.59

MDL编号:

MFCD00133140

UNSPSC代码:

41116107

PubChem化学物质编号:

329831413

NACRES:

NA.24

推荐产品

Slide 1 of 10

1 of 10

Y0000641

阿齐霉素二水合物

B1040000

Betamethasone dipropionate

USP

1067704

Betamethasone dipropionate

B0305000

二丙酸倍氯米松

Y0000637

阿齐霉素二水合物

Y0000473

Calcipotriol monohydrate

Y0000307

阿奇霉素杂质 A

Y0001925

倍他米松

M2900000

Mometasone furoate

Supelco

PHR1619

二丙酸倍氯米松

等级

pharmaceutical primary standard

API类

betamethasone

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

[H][C@@]12C[C@H](C)[C@](OC(=O)CCl)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)C3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

1S/C27H34ClFO7/c1-5-22(33)35-14-21(32)27(36-23(34)13-28)15(2)10-19-18-7-6-16-11-17(30)8-9-24(16,3)26(18,29)20(31)12-25(19,27)4/h8-9,11,15,18-20,31H,5-7,10,12-14H2,1-4H3/t15-,18-,19-,20-,24-,25-,26?,27-/m0/s1

InChI key

UOCNBCVPZWLUKX-HOBFILNXSA-N

正在寻找类似产品? 访问产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Betamethasone dipropionate for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

Betamethasone 17,21-dipropionate is a glucocorticoid with anti-inflammatory and immunosuppressive activity.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

1067045

1067726

Betamethasone Dipropionate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1067737

Betamethasone Dipropionate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1067760

Betamethasone Dipropionate Related Compound F , United States Pharmacopeia (USP) Reference Standard

1067781

Betamethasone dipropionate Related Compound H, United States Pharmacopeia (USP) Reference Standard

象形图

GHS08

警示用语：

Danger

危险声明

H360FD,H373

预防措施声明

P202 - P260 - P280 - P308 + P313 - P405 - P501

危险分类

Repr. 1B - STOT RE 2

靶器官

Liver,Kidney,Endocrine system

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

监管及禁止进口产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland.

Andrew G Affleck et al.

Current medical research and opinion, 27(1), 269-284 (2010-12-15)

To compare the cost effectiveness of the two-compound formulation (TCF) calcipotriol plus betamethasone dipropionate gel used first-, second- or third-line to standard topical treatments for moderately severe scalp psoriasis from a Scottish NHS perspective. Treatment pathways for scalp psoriasis patients

Mixed treatment comparison of a two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate with other topical treatments in psoriasis vulgaris.

Peter van de Kerkhof et al.

Current medical research and opinion, 27(1), 225-238 (2010-12-15)

The efficacy of the two-compound formulation (TCF) product containing calcipotriol and betamethasone dipropionate applied once daily in psoriasis has been demonstrated in phase III trials but no randomised clinical trial comparing all commonly used topical treatments exists. The aim of

Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp.

Paul L McCormack

Drugs, 71(6), 709-730 (2011-04-21)

Calcipotriol/betamethasone dipropionate (calcipotriol 50 μg/g and betamethasone 0.5 mg/g) is a fixed-dose combination of a vitamin D(3) analogue and a corticosteroid indicated for the once-daily, topical treatment of psoriasis vulgaris of the trunk, limbs and scalp in adults. Both the ointment (Daivobet®;

A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity.

P C M van de Kerkhof et al.

Dermatology (Basel, Switzerland), 210(4), 294-299 (2005-06-09)

A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. To determine the effectiveness of the two-compound product in patients with

Spotlight on calcipotriene/betamethasone dipropionate in psoriasis vulgaris of the trunk, limbs, and scalp.

Paul L McCormack

American journal of clinical dermatology, 12(6), 421-424 (2011-10-05)

Calcipotriene (calcipotriol)/betamethasone dipropionate (calcipotriene 50 μg/g and betamethasone 0.5 mg/g) is a fixed-dose combination of a vitamin D3 analog and a corticosteroid indicated for the once-daily, topical treatment of psoriasis vulgaris of the trunk, limbs, and scalp in adults. Both

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

主要文件

安全信息

Betamethasone dipropionate for peak identification

European Pharmacopoeia (EP) Reference Standard

About This Item

推荐产品

属性

等级

API类

制造商/商品名称

应用

包装形式

储存温度

SMILES字符串

InChI

InChI key

说明

一般描述

应用

生化/生理作用

包装

其他说明

相关产品

相关产品

安全信息

象形图

警示用语：

危险声明

预防措施声明

危险分类

靶器官

储存分类代码

WGK

闪点(°F)

闪点(°C)

法规信息

文件

分析证书(COA)

已有该产品？

同行评审论文

技术服务